Valeant Pharmaceuticals International (VRX) · page 26 of 39
This slide is designed to defend Pershing Square against potential accusations of complicity or prior knowledge regarding Valeant's controversial Philidor acquisition.
Activist deck · preempt_rebuttal · preempt_rebuttal · balanced density
Slide locked Sign in to view
Slide schematic 2/2
list 1/1 title 1/1
Components 2
bullet headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1